| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66:115-132.
|
| [2] |
Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol, 2013, 10: 472-484.
|
| [3] |
Alix-Panabieres C and Pantel K Circulating Tumor Cells: Liquid Biopsy of Cancer. Clin Chem, 2013, 59: 110-118.
|
| [4] |
Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol, 2012, 13: 688-695.
|
| [5] |
Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, et al. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win Transl Lung Cancer Res, 2016, 5: 466-482.
|
| [6] |
Mostert B, Sleijfer S, Foekens JA, et al. Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treat Rev, 2009, 35: 463-474.
|
| [7] |
Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 2007, 450: 1235.
|
| [8] |
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med, 2004, 351: 781-791.
|
| [9] |
Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res, 2007, 13: 2023-2229.
|
| [10] |
Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA. Nat Med, 2014, 20: 474-475.
|
| [11] |
Takai E, Yachida S. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroentero, 2016, 22: 8480-8488.
|
| [12] |
Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget, 2016, 7: 48832-48841.
|
| [13] |
Rothe F, Laes JF, Lambrechts D, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol, 2014, 25: 1959-1965.
|
| [14] |
Lancet O. Liquid cancer biopsy: the future of cancer detection. Lancet Oncol, 2016, 17: 123.
|
| [15] |
Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med, 2016, 375: 1289-1294.
|
| [16] |
Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 2014, 158: 1110-1122.
|
| [17] |
Nel I, David P, Gerken GG, et al. Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma. Hepatol Int, 2014, 8: 321-329.
|
| [18] |
Ogle LF, Orr JG, Willoughby CE, et al. Imagestream detection and characterisation of circulating tumour cells-A liquid biopsy for hepatocellular carcinoma. J Hepatol, 2016, 65: 305-313.
|
| [19] |
Liu YK, Hu BS, Li ZL, et al. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int, 2016, 10: 640-646.
|
| [20] |
Liu ZX, Guo WX, Zhang DD, et al. Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry. Sci Rep, 2016, 6.
|
| [21] |
Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57: 1458-1468.
|
| [22] |
Li WD, Zhou X, Huang ZJ, et al. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. Surg Endosc, 2015, 29: 3146-3153.
|
| [23] |
Zhu L, Zhang W, Wang JH, et al. Evidence of CD90+CXCR4+cells as circulating tumor stem cells in hepatocellular carcinoma. Tumor Biol, 2015, 36: 5353-5360.
|
| [24] |
Yan J, Fan ZC, Wu XF, et al. Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytom Part A, 2015, 87A: 1020-1028.
|
| [25] |
Huang JW, Liu B, Hu BS, et al. Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy (Retracted article. See vol. 31, 277, 2014). Med Oncol, 2014, 31: 5.
|
| [26] |
Jiang P, Chan CW, Chan KC, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA, 2015, 112: E1317-E1325.
|
| [27] |
Huang A, Zhang X, Zhou SL, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer, 2016, 7: 1907-1914.
|
| [28] |
Liao WJ, Yang HY, Xu HF, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget, 2016, 7: 40481-40490.
|
| [29] |
Piciocchi M, Cardin R, Vitale A, et al. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int, 2013, 7: 1050-1057.
|
| [30] |
Ono A, Fujimoto A, Yamamoto Y, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol, 2015, 1: 516-534.
|
